Financials data is unavailable for this security.
View more
Year on year Surmodics Inc grew revenues 32.65% from 99.95m to 132.58m. Additionally the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as percentages of sales). These changes narrowed profitability losses from -27.27m to -1.54m.
Gross margin | 74.02% |
---|---|
Net profit margin | -1.16% |
Operating margin | -6.19% |
Return on assets | -0.76% |
---|---|
Return on equity | -1.21% |
Return on investment | -0.89% |
More ▼
Cash flow in USDView more
In 2023, Surmodics Inc increased its cash reserves by 118.02%, or 22.42m. Cash Flow from Financing totalled 18.41m or 13.88% of revenues. In addition the company generated 10.51m in cash from operations while cash used for investing totalled 6.82m.
Cash flow per share | 0.5176 |
---|---|
Price/Cash flow per share | 76.07 |
Book value per share | 8.28 |
---|---|
Tangible book value per share | 3.58 |
More ▼
Balance sheet in USDView more
Current ratio | 3.98 |
---|---|
Quick ratio | 3.22 |
Total debt/total equity | 0.2498 |
---|---|
Total debt/total capital | 0.1999 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items increased 94.41%.
EPS growth(5 years) | -- |
---|---|
EPS (TTM) vs TTM 1 year ago | 94.20 |